Brokers Issue Forecasts for Alnylam Pharmaceuticals, Inc.’s Q1 2018 Earnings (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at FBR & Co issued their Q1 2018 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday. FBR & Co analyst M. Kumar expects that the biopharmaceutical company will earn ($1.25) per share for the quarter. FBR & Co currently has a “Buy” rating and a $150.00 target price on the stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The firm had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.05) earnings per share. TRADEMARK VIOLATION WARNING: “Brokers Issue Forecasts for Alnylam Pharmaceuticals, Inc.’s Q1 2018 Earnings (ALNY)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/02/brokers-issue-forecasts-for-alnylam-pharmaceuticals-inc-s-q1-2018-earnings-alny.html.
ALNY has been the subject of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Nomura started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. They set a “reduce” rating and a $56.00 price objective for the company. ValuEngine raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Instinet started coverage on shares of Alnylam Pharmaceuticals in a research note on Friday, September 15th. They set a “reduce” rating and a $56.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $105.11.
Hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. grew its holdings in Alnylam Pharmaceuticals by 22.0% during the second quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after purchasing an additional 2,093 shares during the last quarter. California Public Employees Retirement System grew its holdings in Alnylam Pharmaceuticals by 14.4% during the second quarter. California Public Employees Retirement System now owns 126,700 shares of the biopharmaceutical company’s stock valued at $10,106,000 after purchasing an additional 15,900 shares during the last quarter. Verition Fund Management LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $1,060,000. Hemenway Trust Co LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $235,000. Finally, Federated Investors Inc. PA grew its holdings in Alnylam Pharmaceuticals by 522.9% during the second quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock valued at $4,968,000 after purchasing an additional 52,293 shares during the last quarter. Institutional investors own 94.39% of the company’s stock.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total value of $4,089,072.36. Following the transaction, the executive vice president now owns 45,201 shares in the company, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders sold 195,797 shares of company stock worth $22,435,072 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.